Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Table 2 Correlation between pembrolizumab activity and outcome and programmed cell death protein ligand 1 immunohistochemestry score

Author/study	Marker antibody	Tumor type	Treatment line	PD-L1 cutoff	N pts	Response	mPFSmo (95%CI)	mOSmo (95%CI)
Pembrolizumab
Garon et al[15] KN001	Dako 22C3	NSCLC	≥ 1	≥ 50%	73	45.20%	6.4 (4.2-NR)	NR (NR-NR)
				1%-49%	103	17%	4.1 (2.3-4.4)	10.6 (7.3-NR)
				< 1%	28	3%	4 (2.1-6.2)	10.4 (5.8-NR)
Herbst et al[16] KN010	Dako 22C3	NSCLC	≥ 2	≥ 50%	290	30%	14.9 (10.4-NR)	5.0 (4.0-6.9)
				1%-49%	400	10%	17.3 (11.8-NR)	5.2 (4.1-8.1)
Reck et al[17] KN024 Phase III	Dako 22C3	NSCLC	1	≥ 50%	305	44.80%	10.3 (6.7-NR)	NA
Langer et al[18] KN021 Phase III	Dako 22C3	Non squamous	1	≥ 50%	20	80%	13 (8.3-NR)	NA
		NSCLC		1%-49%	19	29%
				< 1%	21	57%

KN: KeyNote; NR: not reported; pts: Patients; NA: Not available; NSCLC: Non-small cell lung cancer; PD-L1: Programmed cell death protein ligand 1; mPFS: Median progression free survival; mOS: Median overall survival.